Loading
The first head-to-head trial among KRAS drugs: Roche's divarasib beat the two approved pills on progression and survival.
Krascendo 1, trial NCT06497556 sponsored by Roche, is the first head-to-head trial among KRAS drugs, comparing divarasib with sotorasib or adagrasib in previously treated KRAS G12C-mutant non-small-cell lung cancer. Roche announced on 2 July 2026 that divarasib showed superior progression-free survival by blinded review and superior overall survival at an interim analysis against the two approved inhibitors, with full data expected at a 2026 congress from a trial of 338 patients. OnCo links it to KRAS as a target and to all three drugs, and notes that Krascendo 2 tests divarasib with pembrolizumab in the first line. Because the numbers are pending and this is the first such comparison, there is no independent replication, and whether a more potent G12C inhibitor changes the modest picture left by CodeBreaK 200 and KRYSTAL-12 is the open question. Divarasib has its own page.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
338 enrolled.
Primary endpoint met with a statistically significant, clinically meaningful improvement per the sponsor (topline 2 July 2026); medians and hazard ratio pending presentation.
SourceStatistically significant OS improvement at the interim analysis per the sponsor; numbers pending.
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (BICR)primary | Divarasib | - | Primary endpoint met with a statistically significant, clinically meaningful improvement per the sponsor (topline 2 July 2026); medians and hazard ratio pending presentation. | - | - | link |
| Sotorasib or adagrasib | - | - | ||||
| Overall survival (interim) | Divarasib | - | Statistically significant OS improvement at the interim analysis per the sponsor; numbers pending. | - | - | link |
| Sotorasib or adagrasib | - | - |
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, KRAS & RAS inhibitors.
Shares Divarasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Roche / Genentech.
Shares Divarasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Roche / Genentech.
Shares Adagrasib, Sotorasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors.
Shares Divarasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Roche / Genentech.
Shares Adagrasib, Sotorasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors.
Shares Sotorasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Non-small-cell lung cancer.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Non-small-cell lung cancer.